Skip to main content

Advertisement

ADVERTISEMENT

Early Breast Cancer News

News
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
07/17/2024
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Results from the SWOG S127 study...
07/17/2024
Oncology
News
07/08/2024
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.
Long-term results from the phase...
07/08/2024
Oncology

Advertisement

Conference Coverage
06/17/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.
According to results from the...
06/17/2024
Oncology
News
04/04/2024

Stephanie Holland

Stephanie Holland
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results...
04/04/2024
Oncology
News
02/09/2024

Stephanie Holland 

Stephanie Holland 
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial...
02/09/2024
Oncology

Advertisement

News
12/08/2023
Allison Casey
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology
News
11/29/2023

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 SOUND study, omitting sentinel lymph node biopsy is safe for patients with early breast cancer who have negative results on ultrasonography of the axillary lymph node when the lack of pathological...
According to results from the phase 3 SOUND study, omitting sentinel lymph node biopsy is safe for patients with early breast cancer who have negative results on ultrasonography of the axillary lymph node when the lack of pathological...
According to results from the...
11/29/2023
Oncology

Advertisement